Published in Immunol Rev on June 01, 1999
Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol (2008) 2.85
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest (2005) 2.55
Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am J Hum Genet (2011) 2.22
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Yersinia pseudotuberculosis disseminates directly from a replicating bacterial pool in the intestine. J Exp Med (2006) 2.11
Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol (2010) 1.98
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol (2009) 1.87
Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus. J Immunol (2009) 1.84
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol (2010) 1.61
Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol (2009) 1.60
Complement and systemic lupus erythematosus. Arthritis Res (2002) 1.58
Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol (2005) 1.55
In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol (2010) 1.54
B Cell-Specific MHC Class II Deletion Reveals Multiple Nonredundant Roles for B Cell Antigen Presentation in Murine Lupus. J Immunol (2015) 1.47
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther (2006) 1.42
The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol (2012) 1.36
Regulatory B cells in autoimmune diseases. Cell Mol Immunol (2013) 1.36
The pathogenesis of lupus nephritis. J Am Soc Nephrol (2013) 1.33
Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol (2002) 1.29
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
B cells and immunological tolerance. J Invest Dermatol (2009) 1.15
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis. J Exp Med (2006) 1.12
A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol (2008) 1.08
Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther (2007) 1.07
Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis (2003) 1.05
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol (2008) 1.03
The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. J Biomed Biotechnol (2011) 0.97
T cells and B cells in lupus nephritis. Semin Nephrol (2007) 0.96
Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol (2012) 0.95
IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol (2011) 0.93
Treating human autoimmune disease by depleting B cells. Ann Rheum Dis (2002) 0.93
B cells are important as antigen presenting cells for induction of MHC-restricted arthritis in transgenic mice. Mol Immunol (2007) 0.91
Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Res Ther (2012) 0.90
Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr Allergy Asthma Rep (2011) 0.89
Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol (2011) 0.89
An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus. J Immunol (2011) 0.88
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med (2010) 0.87
Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol (2015) 0.86
To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. J Autoimmun (2011) 0.86
Host factors influencing viral persistence. Philos Trans R Soc Lond B Biol Sci (2000) 0.85
The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. Thromb Haemost (2011) 0.85
Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice. Immunology (2013) 0.85
Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway. Ann Rheum Dis (2006) 0.83
Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc Natl Acad Sci U S A (2006) 0.82
B cells as effectors and regulators of sex-biased arthritis. Autoimmunity (2012) 0.82
SLE - Rituximab in lupus. Arthritis Res Ther (2003) 0.81
Thyrotrophin receptor-specific memory T cell responses require normal B cells in a murine model of Graves' disease. Clin Exp Immunol (2003) 0.79
Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice. PLoS One (2014) 0.79
Reconstitution of the adult B cell repertoire after treatment with rituximab. Arthritis Res Ther (2005) 0.79
Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up. Yonsei Med J (2010) 0.78
Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases. J Clin Med (2017) 0.78
Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice. Evid Based Complement Alternat Med (2014) 0.77
Regulatory T cells in B-cell-deficient and wild-type mice differ functionally and in expression of cell surface markers. Immunology (2015) 0.77
Indications for use and safety of rituximab in childhood renal diseases. Pediatr Nephrol (2012) 0.77
NF-κB in inflammation and renal diseases. Cell Biosci (2015) 0.77
Several Critical Cell Types, Tissues, and Pathways Are Implicated in Genome-Wide Association Studies for Systemic Lupus Erythematosus. G3 (Bethesda) (2016) 0.76
Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res (2011) 0.76
Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol (2016) 0.75
Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis (2001) 0.75
Contribution of alphabeta and gammadelta T cells to the generation of primary immunoglobulin G-driven autoimmune response in immunoglobulin- mu-deficient/lpr mice. Immunology (2004) 0.75
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. Br J Clin Pharmacol (2016) 0.75
Two negative randomized controlled trials in lupus: now what? F1000 Med Rep (2009) 0.75
The role of B cells and autoantibodies in neuropsychiatric lupus. Autoimmun Rev (2016) 0.75
Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives. ScientificWorldJournal (2013) 0.75
Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis. Front Immunol (2017) 0.75
CD5+ B lymphocytes in systemic lupus erythematosus patients: relation to disease activity. Clin Rheumatol (2017) 0.75
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
The role of clonal selection and somatic mutation in autoimmunity. Nature (1987) 4.66
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 2.61
A new role for complement in experimental membranous nephropathy in rats. J Clin Invest (1980) 2.11
Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol (1987) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells. J Exp Med (1986) 2.04
Germinal center initiation, variable gene region hypermutation, and mutant B cell selection without detectable immune complexes on follicular dendritic cells. J Exp Med (2000) 2.03
Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int (1992) 2.01
A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol (1998) 1.95
Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J Immunol (1998) 1.89
Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol (1984) 1.85
Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med (2000) 1.63
Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum (1990) 1.60
A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J Exp Med (1996) 1.58
B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol (1999) 1.54
Propagation and regulation of systemic autoimmunity by gammadelta T cells. J Immunol (1996) 1.52
Immunochemical similarities between monoclonal antibacterial Waldenstrom's macroglobulins and monoclonal anti-DNA lupus autoantibodies. J Exp Med (1985) 1.49
The roles of B cells in MRL/lpr murine lupus. Ann N Y Acad Sci (1997) 1.49
A B-cell receptor-specific selection step governs immature to mature B cell differentiation. Proc Natl Acad Sci U S A (2000) 1.42
Murine lupus in the absence of alpha beta T cells. J Immunol (1996) 1.41
Lupus prone (SWR x NZB)F1 mice produce potentially nephritogenic autoantibodies inherited from the normal SWR parent. J Immunol (1985) 1.37
Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol (1992) 1.34
V region gene analysis of anti-Sm hybridomas from MRL/Mp-lpr/lpr mice. J Immunol (1993) 1.32
The role of environmental antigens in the spontaneous development of autoimmunity in MRL-lpr mice. J Immunol (1999) 1.30
Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest (1993) 1.30
Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol (1987) 1.27
Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med (1999) 1.23
Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol (1996) 1.21
Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol (2001) 1.20
Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest (1997) 1.14
Pathogenic autoantibodies in lupus nephritis. Lupus (2005) 1.11
A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, the major non-collagenous protein component of the glomerular basement membrane. Eur J Immunol (1989) 1.09
The mechanism of autoantibody production in an autoimmune MRL/lpr mouse. J Immunol (1994) 1.08
Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J Immunol (2001) 1.07
Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int (1996) 1.07
Molecular analysis of spontaneous nephrotropic anti-laminin antibodies in an autoimmune MRL-lpr/lpr mouse. J Immunol (1993) 1.05
Antibody is required for clearance of infectious murine hepatitis virus A59 from the central nervous system, but not the liver. J Immunol (2001) 1.04
Dual infection with Pneumocystis carinii and Pasteurella pneumotropica in B cell-deficient mice: diagnosis and therapy. Comp Med (2000) 1.03
Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int (1983) 0.99
Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. Kidney Int (1983) 0.98
Lupus serum and normal human serum contain anti-DNA antibodies with the same idiotypic marker. J Immunol (1986) 0.98
Factors influencing glomerular and tubulointerstitial patterns of injury in SLE. Am J Kidney Dis (1982) 0.98
Fas/Fas ligand deficiency results in altered localization of anti-double-stranded DNA B cells and dendritic cells. J Immunol (2001) 0.98
Pathogenesis of autoimmunity in alphabeta T cell-deficient lupus-prone mice. Clin Exp Immunol (1998) 0.97
Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun (1990) 0.97
A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner. Lab Invest (1994) 0.96
alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol (1997) 0.96
Independently derived murine glomerular immune deposit-forming anti-DNA antibodies are encoded by near-identical VH gene sequences. J Clin Invest (1993) 0.95
Alterations in splenic architecture and the localization of anti-double-stranded DNA B cells in aged mice. Int Immunol (2000) 0.94
Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol (2000) 0.94
Effect of antibody charge and concentration on deposition of antibody to glomerular basement membrane. Kidney Int (1984) 0.92
Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis (1991) 0.92
Altered glomerular permeability induced by F(ab')2 and Fab' antibodies to rat renal tubular epithelial antigen. Kidney Int (1982) 0.91
Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int (2006) 0.90
Anti-DNA antibodies bind to DNase I. J Exp Med (1995) 0.89
High affinity rheumatoid factor transgenic B cells are eliminated in normal mice. J Immunol (1997) 0.87
Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med (1996) 0.87
Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood (2001) 0.86
Cutting edge: B cells promote CD8+ T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation. J Immunol (2000) 0.86
Maternal Ig mediates neonatal tolerance in rheumatoid factor transgenic mice but tolerance breaks down in adult mice. J Immunol (1998) 0.85
Human and murine anti-DNA antibodies induce the production of anti-idiotypic antibodies with autoantigen-binding properties (epibodies) through immune-network interactions. J Immunol (1990) 0.85
Isolation and flow cytometric analysis of T-cell-depleted CD34+ PBPCs. Transfusion (2000) 0.85
VH gene analysis of spontaneously activated B cells in adult MRL-lpr/lpr mice. J558 bias is not limited to classic lupus autoantibodies. J Immunol (1991) 0.85
Glomerular filtration rate and urinary albumin excretion rate in systemic lupus erythematosus. Nephron (1995) 0.85
The origin of anti-nuclear antibodies in bcl-2 transgenic mice. Int Immunol (2000) 0.84
Autoreactive T cells from MRL-lpr/lpr mice secrete multiple lymphokines and induce the production of IgG anti-DNA antibodies. J Autoimmun (1991) 0.84
Restriction fragment length polymorphism analysis of the V kappa locus in human lupus. Eur J Immunol (1989) 0.84
Lupus autoantibodies 101: one size does not fit all; however, specificity influences pathogenicity. Clin Exp Immunol (2003) 0.83
High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int (2000) 0.83
Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal. J Am Soc Nephrol (1996) 0.82
Current concepts. The diagnosis of acute glomerulonephritis. N Engl J Med (1983) 0.82
Charge selective properties of the glomerular capillary wall influence antibody binding in rat membranous nephropathy. Clin Immunol Immunopathol (1986) 0.82
Structural properties of a subset of nephritogenic anti-DNA antibodies. Immunol Res (1994) 0.82
Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies. Immunol Res (1994) 0.81
Human Goodpasture anti-alpha3(IV)NC1 autoantibodies share structural determinants. Kidney Int (1998) 0.81
Structural features of nephritogenic lupus autoantibodies. Methods (1997) 0.80
Induction of anti-DNA antibodies in non autoimmune mice by immunization with a DNA-DNAase I complex. Clin Exp Rheumatol (1995) 0.80
Selection of specific phage from display libraries: monoclonal antibody against VCS M13 helper phage coat protein III (gIIIp). Hybridoma (1999) 0.79
T cells reactive to an inducible heat shock protein induce disease in toxin-induced interstitial nephritis. J Exp Med (1994) 0.79
Variable region sequence analysis of anti-DNA antibodies: evidence for a family of closely related germ-line VH genes encoding lupus autoantibodies. DNA Cell Biol (1992) 0.78
Systemic autoimmunity in LG/J mice. Immunol Lett (1996) 0.78
Are DNA antibodies actually pathogenic? Lupus (1997) 0.78
Autoreactive T cells with atypical MHC restriction from MRL-lpr/lpr mice: forbidden clones revisited. J Mol Cell Immunol (1988) 0.78
Abnormal signal transduction through CD4 leads to altered tyrosine phosphorylation in T cells derived from MRL-lpr/lpr mice. Autoimmunity (1996) 0.77
Glomerular localization of circulating single-stranded DNA in mice. Dependence on the molecular weight of DNA. J Autoimmun (1988) 0.77
Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol (1997) 0.77
Idiotype usage by polyclonally activated B cells in experimental autoimmunity and infection. Clin Exp Immunol (1999) 0.77
Vaccination against pathogenic cells by DNA inoculation. Curr Top Microbiol Immunol (1998) 0.76
Cyclophosphamide in progressive membranous glomerulopathy: pro and con. Ann Intern Med (1992) 0.75
Anti-DNA idiotype network: therapeutic considerations. Lupus (1992) 0.75
Diagnosis and treatment of nephrotic syndrome. Expert Opin Investig Drugs (1999) 0.75
A monoclonal autoantibody against a complementary peptide recognizes interstitial collagenase. Immunomethods (1994) 0.75